Glaukos Corporation (GKOS) Earnings Call Analysis
NYSE · Healthcare · Medical Devices
Earnings Reports
-
Glaukos (GKOS) Q2 2026: Epioxa Drives 90bps Gross Margin Gain as Launch Momentum Builds
July 30, 2026
-
Glaukos (GKOS) Q1 2026: iDoseTR Drives 58% U.S. Glaucoma Surge, Epioxa Launch Expands Access
April 30, 2026
-
Glaukos (GKOS) Q4 2025: iDose-TR Drives 53% U.S. Glaucoma Growth, Epioxa Launch Sets Up 2H Surge
February 24, 2026
-
GKOS Q3 2025: Epioxa Approval Sets $78K Rare Disease Pricing, Anchoring 2026 Growth Outlook
October 29, 2025
-
Glaukos (GKOS) Q2 2025: iDose TR Drives 45% U.S. Glaucoma Growth, Reshaping Ophthalmology Playbook
July 30, 2025
-
Glaukos (GKOS) Q1 2025: iDose-TR Drives 41% U.S. Glaucoma Growth, Offsetting Stent Declines
July 04, 2025